Upcoming Events
World Vaccine Congress Washington 2027
8-11 March 2027
Walter E. Washington Convention Center
Washington D.C.
Details | Brochure | Register
World Vaccine Congress Europe 2027
25-27 October 2027
Lyon Convention Centre
Lyon
Details | Brochure | Register
MOST POPULAR THIS MONTH
UK begins Phase III trial of mRNA norovirus vaccine
The National Institute for Health and Care Research (NIHR) announced in October 2024 that the first Phase III randomised trial of an investigational mRNA norovirus vaccine is opening across the UK. The trial seeks to evaluate the efficacy and safety of mRNA-1403 and...
WHO declares Egypt malaria-free after 100-year effort
In October 2024 WHO certified Egypt as malaria-free after a “nearly 100-year effort” by the government and people to end the disease. WHO described this as a “significant public health milestone” for the country’s more than 100 million inhabitants. Egypt is the third...
Bacterial vectors for precision cancer vaccine development
Research in Nature in October 2024 leverages evidence that bacteria “naturally home in on tumours and modulate antitumour immunity” to explore potential vaccine applications. The authors engineered a probiotic Escherichia coli Nissle 1917as an antitumour vaccination...
Global Polio Eradication Initiative faces challenges
The Global Polio Eradication Initiative (GPEI) announced the “difficult decision” to extend the timelines needed to achieve polio eradication. This decision, made by the Polio Oversight Board (POB) in July 2024, was shared in October 2024 with an update to funding...
The Vaccine Group and APHA secure animal vaccine grant
In October 2024 the Animal and Plant Health Agency (APHA) and The Vaccine Group (TVG) announced that Innovate UK has awarded them a Smart grant in excess of £400,000 to advance a novel viral vector platform. In a project lasting 19 months, the two organisations will...
Valneva and LimmaTech secure Shigella vaccine fast track
Valneva and LimmaTech Biologics announced in October 2024 that they have been granted Fast Track designation by the United States FDA for Shigella4V (S4V). S4V is “the world’s most clinically advanced” tetravalent bioconjugate shigellosis vaccine candidate. In August...
Modelling study: 100 Days Mission demands vaccine equity
A study in The Lancet Global Health estimates the impact that the 100 Days Mission could have had on the COVID-19 pandemic. The authors find that the implementation of non-pharmaceutical interventions (NPIs) within the 100 Days Mission could have averted around 8.33...
Parliamentarians support Pandemic Agreement efforts
In October 2024, parliamentarians from across the world met at the UNITE Global Summit in Berlin to sign a statement in support of the WHO Pandemic Agreement. The statement was described by WHO as a “significant commitment” to “strengthen pandemic preparedness,...
